APO Research
Talk to an analyst

APO RESEARCH · REPORT

VEGFR-2 Inhibitor

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global VEGFR-2 Inhibitor Industry Growth and Trends Forecast to 2032

27 December 202596 pages

Choose your research edition.

Industry ResearchVEGFR-2 Inhibitor Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal VEGFR-2 Inhibitor Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal VEGFR-2 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal VEGFR-2 Inhibitor Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal VEGFR-2 Inhibitor Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global VEGFR-2 Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for VEGFR-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for VEGFR-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for VEGFR-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of VEGFR-2 Inhibitor include AstraZeneca, Bayer, Boehringer Ingelheim, Eisai, Exelixis, Novartis, Pfizer, Jiangsu Hengrui Pharmaceuticals and Chia Tai Tianqing, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global VEGFR-2 Inhibitor market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The VEGFR-2 Inhibitor market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global VEGFR-2 Inhibitor market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to VEGFR-2 Inhibitor.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global VEGFR-2 Inhibitor market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

VEGFR-2 Inhibitor Market by Company

AstraZeneca

Bayer

Boehringer Ingelheim

Eisai

Exelixis

Novartis

Pfizer

Jiangsu Hengrui Pharmaceuticals

Chia Tai Tianqing

VEGFR-2 Inhibitor Segment by Type

Sorafenib

Sunitinib

Nintedanib

Lenvatinib

Cabozantinib

Vandetanib

Apatinib

Other

VEGFR-2 Inhibitor Segment by Application

Ophthalmic Diseases

Cancer Therapy

Other

VEGFR-2 Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VEGFR-2 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of VEGFR-2 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VEGFR-2 Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of VEGFR-2 Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of VEGFR-2 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Sorafenib Table 2. Major Company of Sunitinib Table 3. Major Company of Nintedanib Table 4. Major Company of Lenvatinib Table 5. Major Company of Cabozantinib Table 6. Major Company of Vandetanib Table 7. Major Company of Apatinib Table 8. Major Company of Other Table 9. Global VEGFR-2 Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 10. Global VEGFR-2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 11. Global VEGFR-2 Inhibitor Sales Market Share in Volume by Type (2021-2026) Table 12. Global VEGFR-2 Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 13. Global VEGFR-2 Inhibitor Sales Market Share in Value by Type (2021-2026) Table 14. Global VEGFR-2 Inhibitor Price by Type (2021-2026) & (US$/Unit) Table 15. Global VEGFR-2 Inhibitor Sales by Type (2027-2032) & (K Units) Table 16. Global VEGFR-2 Inhibitor Sales Market Share in Volume by Type (2027-2032) Table 17. Global VEGFR-2 Inhibitor Sales by Type (2027-2032) & (US$ Million) Table 18. Global VEGFR-2 Inhibitor Sales Market Share in Value by Type (2027-2032) Table 19. Global VEGFR-2 Inhibitor Price by Type (2027-2032) & (US$/Unit) Table 20. North America VEGFR-2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 21. North America VEGFR-2 Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 22. Europe VEGFR-2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 23. Europe VEGFR-2 Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 24. Asia-Pacific VEGFR-2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 25. Asia-Pacific VEGFR-2 Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 26. Latin America VEGFR-2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 27. Latin America VEGFR-2 Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 28. Middle East and Africa VEGFR-2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 29. Middle East and Africa VEGFR-2 Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 30. VEGFR-2 Inhibitor Industry Trends Table 31. VEGFR-2 Inhibitor Industry Drivers Table 32. VEGFR-2 Inhibitor Industry Opportunities and Challenges Table 33. VEGFR-2 Inhibitor Industry Restraints Table 34. Global VEGFR-2 Inhibitor Sales Revenue by Company (US$ Million) & (2021-2026) Table 35. Global VEGFR-2 Inhibitor Revenue Market Share by Company (2021-2026) Table 36. Global VEGFR-2 Inhibitor Sales by Company (2021-2026) & (K Units) Table 37. Global VEGFR-2 Inhibitor Sales Share by Company (2021-2026) Table 38. Global VEGFR-2 Inhibitor Market Price by Company (2021-2026) & (US$/Unit) Table 39. Global VEGFR-2 Inhibitor Industry Company Ranking, 2024 VS 2025 VS 2026 Table 40. Global VEGFR-2 Inhibitor Major Company Production Sites and Headquarters Table 41. Global VEGFR-2 Inhibitor Company, Product Type & Application Table 42. Global VEGFR-2 Inhibitor Company Establishment Date Table 43. Global Company Market Concentration Ratio (CR5 and HHI) Table 44. Global VEGFR-2 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 45. Global VEGFR-2 Inhibitor Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 46. Global VEGFR-2 Inhibitor Sales by Region (2021-2026) & (K Units) Table 47. Global VEGFR-2 Inhibitor Sales Market Share in Volume by Region (2021-2026) Table 48. Global VEGFR-2 Inhibitor Sales by Region (2021-2026) & (US$ Million) Table 49. Global VEGFR-2 Inhibitor Sales Market Share in Value by Region (2021-2026) Table 50. Global VEGFR-2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Global VEGFR-2 Inhibitor Sales by Region (2027-2032) & (K Units) Table 52. Global VEGFR-2 Inhibitor Sales Market Share in Volume by Region (2027-2032) Table 53. Global VEGFR-2 Inhibitor Sales by Region (2027-2032) & (US$ Million) Table 54. Global VEGFR-2 Inhibitor Sales Market Share in Value by Region (2027-2032) Table 55. Global VEGFR-2 Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 56. Global VEGFR-2 Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 57. Global VEGFR-2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 58. Global VEGFR-2 Inhibitor Sales Market Share in Volume by Application (2021-2026) Table 59. Global VEGFR-2 Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 60. Global VEGFR-2 Inhibitor Sales Market Share in Value by Application (2021-2026) Table 61. Global VEGFR-2 Inhibitor Price by Application (2021-2026) & (US$/Unit) Table 62. Global VEGFR-2 Inhibitor Sales by Application (2027-2032) & (K Units) Table 63. Global VEGFR-2 Inhibitor Sales Market Share in Volume by Application (2027-2032) Table 64. Global VEGFR-2 Inhibitor Sales by Application (2027-2032) & (US$ Million) Table 65. Global VEGFR-2 Inhibitor Sales Market Share in Value by Application (2027-2032) Table 66. Global VEGFR-2 Inhibitor Price by Application (2027-2032) & (US$/Unit) Table 67. North America VEGFR-2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 68. North America VEGFR-2 Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 69. Europe VEGFR-2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 70. Europe VEGFR-2 Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 71. Asia-Pacific VEGFR-2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 72. Asia-Pacific VEGFR-2 Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 73. Latin America VEGFR-2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 74. Latin America VEGFR-2 Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 75. Middle East and Africa VEGFR-2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 76. Middle East and Africa VEGFR-2 Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 77. AstraZeneca Company Information Table 78. AstraZeneca Business Overview Table 79. AstraZeneca VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. AstraZeneca VEGFR-2 Inhibitor Product Portfolio Table 81. AstraZeneca Recent Development Table 82. Bayer Company Information Table 83. Bayer Business Overview Table 84. Bayer VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Bayer VEGFR-2 Inhibitor Product Portfolio Table 86. Bayer Recent Development Table 87. Boehringer Ingelheim Company Information Table 88. Boehringer Ingelheim Business Overview Table 89. Boehringer Ingelheim VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Boehringer Ingelheim VEGFR-2 Inhibitor Product Portfolio Table 91. Boehringer Ingelheim Recent Development Table 92. Eisai Company Information Table 93. Eisai Business Overview Table 94. Eisai VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Eisai VEGFR-2 Inhibitor Product Portfolio Table 96. Eisai Recent Development Table 97. Exelixis Company Information Table 98. Exelixis Business Overview Table 99. Exelixis VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Exelixis VEGFR-2 Inhibitor Product Portfolio Table 101. Exelixis Recent Development Table 102. Novartis Company Information Table 103. Novartis Business Overview Table 104. Novartis VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Novartis VEGFR-2 Inhibitor Product Portfolio Table 106. Novartis Recent Development Table 107. Pfizer Company Information Table 108. Pfizer Business Overview Table 109. Pfizer VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Pfizer VEGFR-2 Inhibitor Product Portfolio Table 111. Pfizer Recent Development Table 112. Jiangsu Hengrui Pharmaceuticals Company Information Table 113. Jiangsu Hengrui Pharmaceuticals Business Overview Table 114. Jiangsu Hengrui Pharmaceuticals VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Jiangsu Hengrui Pharmaceuticals VEGFR-2 Inhibitor Product Portfolio Table 116. Jiangsu Hengrui Pharmaceuticals Recent Development Table 117. Chia Tai Tianqing Company Information Table 118. Chia Tai Tianqing Business Overview Table 119. Chia Tai Tianqing VEGFR-2 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Chia Tai Tianqing VEGFR-2 Inhibitor Product Portfolio Table 121. Chia Tai Tianqing Recent Development Table 122. North America VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 123. North America VEGFR-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 124. North America VEGFR-2 Inhibitor Sales Market Share by Country (2021-2026) Table 125. North America VEGFR-2 Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 126. North America VEGFR-2 Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 127. North America VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 128. North America VEGFR-2 Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 129. North America VEGFR-2 Inhibitor Market Share by Country (2021-2026) Table 130. North America VEGFR-2 Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 131. North America VEGFR-2 Inhibitor Market Share Forecast by Country (2027-2032) Table 132. Europe VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 133. Europe VEGFR-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 134. Europe VEGFR-2 Inhibitor Sales Market Share by Country (2021-2026) Table 135. Europe VEGFR-2 Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 136. Europe VEGFR-2 Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 137. Europe VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. Europe VEGFR-2 Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 139. Europe VEGFR-2 Inhibitor Market Share by Country (2021-2026) Table 140. Europe VEGFR-2 Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. Europe VEGFR-2 Inhibitor Market Share Forecast by Country (2027-2032) Table 142. Asia-Pacific VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 143. Asia-Pacific VEGFR-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 144. Asia-Pacific VEGFR-2 Inhibitor Sales Market Share by Country (2021-2026) Table 145. Asia-Pacific VEGFR-2 Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 146. Asia-Pacific VEGFR-2 Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 147. Asia-Pacific VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Asia-Pacific VEGFR-2 Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 149. Asia-Pacific VEGFR-2 Inhibitor Market Share by Country (2021-2026) Table 150. Asia-Pacific VEGFR-2 Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Asia-Pacific VEGFR-2 Inhibitor Market Share Forecast by Country (2027-2032) Table 152. Latin America VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 153. Latin America VEGFR-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 154. Latin America VEGFR-2 Inhibitor Sales Market Share by Country (2021-2026) Table 155. Latin America VEGFR-2 Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 156. Latin America VEGFR-2 Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 157. Latin America VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. Latin America VEGFR-2 Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 159. Latin America VEGFR-2 Inhibitor Market Share by Country (2021-2026) Table 160. Latin America VEGFR-2 Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. Latin America VEGFR-2 Inhibitor Market Share Forecast by Country (2027-2032) Table 162. Middle East and Africa VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 163. Middle East and Africa VEGFR-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 164. Middle East and Africa VEGFR-2 Inhibitor Sales Market Share by Country (2021-2026) Table 165. Middle East and Africa VEGFR-2 Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 166. Middle East and Africa VEGFR-2 Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 167. Middle East and Africa VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 168. Middle East and Africa VEGFR-2 Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 169. Middle East and Africa VEGFR-2 Inhibitor Market Share by Country (2021-2026) Table 170. Middle East and Africa VEGFR-2 Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 171. Middle East and Africa VEGFR-2 Inhibitor Market Share Forecast by Country (2027-2032) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. VEGFR-2 Inhibitor Distributors List Table 175. VEGFR-2 Inhibitor Customers List Table 176. Research Programs/Design for This Report Table 177. Authors List of This Report Table 178. Secondary Sources Table 179. Primary Sources List of Figures Figure 1. VEGFR-2 Inhibitor Image Figure 2. Global VEGFR-2 Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global VEGFR-2 Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global VEGFR-2 Inhibitor Sales (2021-2032) & (K Units) Figure 5. Sorafenib Image Figure 6. Global Sorafenib Sales YoY Growth (2021-2032) & (K Units) Figure 7. Sunitinib Image Figure 8. Global Sunitinib Sales YoY Growth (2021-2032) & (K Units) Figure 9. Nintedanib Image Figure 10. Global Nintedanib Sales YoY Growth (2021-2032) & (K Units) Figure 11. Lenvatinib Image Figure 12. Global Lenvatinib Sales YoY Growth (2021-2032) & (K Units) Figure 13. Cabozantinib Image Figure 14. Global Cabozantinib Sales YoY Growth (2021-2032) & (K Units) Figure 15. Vandetanib Image Figure 16. Global Vandetanib Sales YoY Growth (2021-2032) & (K Units) Figure 17. Apatinib Image Figure 18. Global Apatinib Sales YoY Growth (2021-2032) & (K Units) Figure 19. Other Image Figure 20. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 21. Global VEGFR-2 Inhibitor Market Size Overview by Type (2021-2032) & (US$ Million) Figure 22. Global VEGFR-2 Inhibitor Market Share by Type 2025 VS 2032 Figure 23. North America VEGFR-2 Inhibitor Sales Market Share in Volume by Type in 2025 Figure 24. North America VEGFR-2 Inhibitor Sales Market Share in Value by Type in 2025 Figure 25. Europe VEGFR-2 Inhibitor Sales Market Share in Volume by Type in 2025 Figure 26. Europe VEGFR-2 Inhibitor Sales Market Share in Value by Type in 2025 Figure 27. Asia-Pacific VEGFR-2 Inhibitor Sales Market Share in Volume by Type in 2025 Figure 28. Asia-Pacific VEGFR-2 Inhibitor Sales Market Share in Value by Type in 2025 Figure 29. Latin America VEGFR-2 Inhibitor Sales Market Share in Volume by Type in 2025 Figure 30. Latin America VEGFR-2 Inhibitor Sales Market Share in Value by Type in 2025 Figure 31. Middle East and Africa VEGFR-2 Inhibitor Sales Market Share in Volume by Type in 2025 Figure 32. Middle East and Africa VEGFR-2 Inhibitor Sales Market Share in Value by Type in 2025 Figure 33. Global Top 5 and 10 VEGFR-2 Inhibitor Players Market Share by Revenue in 2025 Figure 34. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 35. Ophthalmic Diseases Image Figure 36. Global Ophthalmic Diseases Sales YoY Growth (2021-2032) & (K Units) Figure 37. Cancer Therapy Image Figure 38. Global Cancer Therapy Sales YoY Growth (2021-2032) & (K Units) Figure 39. Other Image Figure 40. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 41. Global VEGFR-2 Inhibitor Market Size Overview by Application (2021-2032) & (US$ Million) Figure 42. Global VEGFR-2 Inhibitor Market Share by Application 2025 VS 2032 Figure 43. North America VEGFR-2 Inhibitor Sales Market Share in Volume by Application in 2025 Figure 44. North America VEGFR-2 Inhibitor Sales Market Share in Value by Application in 2025 Figure 45. Europe VEGFR-2 Inhibitor Sales Market Share in Volume by Application in 2025 Figure 46. Europe VEGFR-2 Inhibitor Sales Market Share in Value by Application in 2025 Figure 47. Asia-Pacific VEGFR-2 Inhibitor Sales Market Share in Volume by Application in 2025 Figure 48. Asia-Pacific VEGFR-2 Inhibitor Sales Market Share in Value by Application in 2025 Figure 49. Latin America VEGFR-2 Inhibitor Sales Market Share in Volume by Application in 2025 Figure 50. Latin America VEGFR-2 Inhibitor Sales Market Share in Value by Application in 2025 Figure 51. Middle East and Africa VEGFR-2 Inhibitor Sales Market Share in Volume by Application in 2025 Figure 52. Middle East and Africa VEGFR-2 Inhibitor Sales Market Share in Value by Application in 2025 Figure 53. North America VEGFR-2 Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. North America VEGFR-2 Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. North America VEGFR-2 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. North America VEGFR-2 Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe VEGFR-2 Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Europe VEGFR-2 Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe VEGFR-2 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Europe VEGFR-2 Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific VEGFR-2 Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Asia-Pacific VEGFR-2 Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific VEGFR-2 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Asia-Pacific VEGFR-2 Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America VEGFR-2 Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 66. Latin America VEGFR-2 Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Latin America VEGFR-2 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Latin America VEGFR-2 Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa VEGFR-2 Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 70. Middle East and Africa VEGFR-2 Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 71. Middle East and Africa VEGFR-2 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 72. Middle East and Africa VEGFR-2 Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 73. VEGFR-2 Inhibitor Value Chain Figure 74. Key Raw Materials Price Figure 75. Manufacturing Cost Structure Figure 76. VEGFR-2 Inhibitor Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Years Considered Figure 80. Research Process Figure 81. Key Executives Interviewed

Scope & coverage.

Types
  • Sorafenib
  • Sunitinib
  • Nintedanib
  • Lenvatinib
  • Cabozantinib
  • Vandetanib
  • Apatinib
  • Other
Applications
  • Ophthalmic Diseases
  • Cancer Therapy
  • Other
Companies covered
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Eisai
  • Exelixis
  • Novartis
  • Pfizer
  • Jiangsu Hengrui Pharmaceuticals
  • Chia Tai Tianqing

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global VEGFR-2 Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global VEGFR-2 Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.3 VEGFR-2 Inhibitor Market by Type
  6. 1.3.1 Sorafenib
  7. 1.3.2 Sunitinib
  8. 1.3.3 Nintedanib
  9. 1.3.4 Lenvatinib
  10. 1.3.5 Cabozantinib
  11. 1.3.6 Vandetanib
  12. 1.3.7 Apatinib
  13. 1.3.8 Other
  14. 1.4 Global VEGFR-2 Inhibitor Market Size by Type
  15. 1.4.1 Global VEGFR-2 Inhibitor Market Size Overview by Type (2021-2032)
  16. 1.4.2 Global VEGFR-2 Inhibitor Historic Market Size Review by Type (2021-2026)
  17. 1.4.3 Global VEGFR-2 Inhibitor Forecasted Market Size by Type (2027-2032)
  18. 1.5 Key Regions Market Size by Type
  19. 1.5.1 North America VEGFR-2 Inhibitor Sales Breakdown by Type (2021-2026)
  20. 1.5.2 Europe VEGFR-2 Inhibitor Sales Breakdown by Type (2021-2026)
  21. 1.5.3 Asia-Pacific VEGFR-2 Inhibitor Sales Breakdown by Type (2021-2026)
  22. 1.5.4 South America VEGFR-2 Inhibitor Sales Breakdown by Type (2021-2026)
  23. 1.5.5 Middle East and Africa VEGFR-2 Inhibitor Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 VEGFR-2 Inhibitor Industry Trends
  2. 2.2 VEGFR-2 Inhibitor Industry Drivers
  3. 2.3 VEGFR-2 Inhibitor Industry Opportunities and Challenges
  4. 2.4 VEGFR-2 Inhibitor Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by VEGFR-2 Inhibitor Revenue (2021-2026)
  2. 3.2 Global Top Players by VEGFR-2 Inhibitor Sales (2021-2026)
  3. 3.3 Global Top Players by VEGFR-2 Inhibitor Price (2021-2026)
  4. 3.4 Global VEGFR-2 Inhibitor Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global VEGFR-2 Inhibitor Major Company Production Sites & Headquarters
  6. 3.6 Global VEGFR-2 Inhibitor Company, Product Type & Application
  7. 3.7 Global VEGFR-2 Inhibitor Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global VEGFR-2 Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 VEGFR-2 Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 VEGFR-2 Inhibitor Tier 1, Tier 2, and Tier 3
4 VEGFR-2 Inhibitor Regional Status and Outlook
  1. 4.1 Global VEGFR-2 Inhibitor Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global VEGFR-2 Inhibitor Historic Market Size by Region
  3. 4.2.1 Global VEGFR-2 Inhibitor Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global VEGFR-2 Inhibitor Sales in Value by Region (2021-2026)
  5. 4.2.3 Global VEGFR-2 Inhibitor Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global VEGFR-2 Inhibitor Forecasted Market Size by Region
  7. 4.3.1 Global VEGFR-2 Inhibitor Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global VEGFR-2 Inhibitor Sales in Value by Region (2027-2032)
  9. 4.3.3 Global VEGFR-2 Inhibitor Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 VEGFR-2 Inhibitor by Application
  1. 5.1 VEGFR-2 Inhibitor Market by Application
  2. 5.1.1 Ophthalmic Diseases
  3. 5.1.2 Cancer Therapy
  4. 5.1.3 Other
  5. 5.2 Global VEGFR-2 Inhibitor Market Size by Application
  6. 5.2.1 Global VEGFR-2 Inhibitor Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global VEGFR-2 Inhibitor Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global VEGFR-2 Inhibitor Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America VEGFR-2 Inhibitor Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe VEGFR-2 Inhibitor Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific VEGFR-2 Inhibitor Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America VEGFR-2 Inhibitor Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa VEGFR-2 Inhibitor Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 AstraZeneca
  2. 6.1.1 AstraZeneca Company Information
  3. 6.1.2 AstraZeneca Business Overview
  4. 6.1.3 AstraZeneca VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 AstraZeneca VEGFR-2 Inhibitor Product Portfolio
  6. 6.1.5 AstraZeneca Recent Developments
  7. 6.2 Bayer
  8. 6.2.1 Bayer Company Information
  9. 6.2.2 Bayer Business Overview
  10. 6.2.3 Bayer VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bayer VEGFR-2 Inhibitor Product Portfolio
  12. 6.2.5 Bayer Recent Developments
  13. 6.3 Boehringer Ingelheim
  14. 6.3.1 Boehringer Ingelheim Company Information
  15. 6.3.2 Boehringer Ingelheim Business Overview
  16. 6.3.3 Boehringer Ingelheim VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Boehringer Ingelheim VEGFR-2 Inhibitor Product Portfolio
  18. 6.3.5 Boehringer Ingelheim Recent Developments
  19. 6.4 Eisai
  20. 6.4.1 Eisai Company Information
  21. 6.4.2 Eisai Business Overview
  22. 6.4.3 Eisai VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Eisai VEGFR-2 Inhibitor Product Portfolio
  24. 6.4.5 Eisai Recent Developments
  25. 6.5 Exelixis
  26. 6.5.1 Exelixis Company Information
  27. 6.5.2 Exelixis Business Overview
  28. 6.5.3 Exelixis VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Exelixis VEGFR-2 Inhibitor Product Portfolio
  30. 6.5.5 Exelixis Recent Developments
  31. 6.6 Novartis
  32. 6.6.1 Novartis Company Information
  33. 6.6.2 Novartis Business Overview
  34. 6.6.3 Novartis VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Novartis VEGFR-2 Inhibitor Product Portfolio
  36. 6.6.5 Novartis Recent Developments
  37. 6.7 Pfizer
  38. 6.7.1 Pfizer Company Information
  39. 6.7.2 Pfizer Business Overview
  40. 6.7.3 Pfizer VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Pfizer VEGFR-2 Inhibitor Product Portfolio
  42. 6.7.5 Pfizer Recent Developments
  43. 6.8 Jiangsu Hengrui Pharmaceuticals
  44. 6.8.1 Jiangsu Hengrui Pharmaceuticals Company Information
  45. 6.8.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  46. 6.8.3 Jiangsu Hengrui Pharmaceuticals VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Jiangsu Hengrui Pharmaceuticals VEGFR-2 Inhibitor Product Portfolio
  48. 6.8.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  49. 6.9 Chia Tai Tianqing
  50. 6.9.1 Chia Tai Tianqing Company Information
  51. 6.9.2 Chia Tai Tianqing Business Overview
  52. 6.9.3 Chia Tai Tianqing VEGFR-2 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Chia Tai Tianqing VEGFR-2 Inhibitor Product Portfolio
  54. 6.9.5 Chia Tai Tianqing Recent Developments
7 North America by Country
  1. 7.1 North America VEGFR-2 Inhibitor Sales by Country
  2. 7.1.1 North America VEGFR-2 Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America VEGFR-2 Inhibitor Sales by Country (2021-2026)
  4. 7.1.3 North America VEGFR-2 Inhibitor Sales Forecast by Country (2027-2032)
  5. 7.2 North America VEGFR-2 Inhibitor Market Size by Country
  6. 7.2.1 North America VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America VEGFR-2 Inhibitor Market Size by Country (2021-2026)
  8. 7.2.3 North America VEGFR-2 Inhibitor Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe VEGFR-2 Inhibitor Sales by Country
  2. 8.1.1 Europe VEGFR-2 Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe VEGFR-2 Inhibitor Sales by Country (2021-2026)
  4. 8.1.3 Europe VEGFR-2 Inhibitor Sales Forecast by Country (2027-2032)
  5. 8.2 Europe VEGFR-2 Inhibitor Market Size by Country
  6. 8.2.1 Europe VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe VEGFR-2 Inhibitor Market Size by Country (2021-2026)
  8. 8.2.3 Europe VEGFR-2 Inhibitor Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific VEGFR-2 Inhibitor Sales by Country
  2. 9.1.1 Asia-Pacific VEGFR-2 Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific VEGFR-2 Inhibitor Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific VEGFR-2 Inhibitor Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific VEGFR-2 Inhibitor Market Size by Country
  6. 9.2.1 Asia-Pacific VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific VEGFR-2 Inhibitor Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific VEGFR-2 Inhibitor Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America VEGFR-2 Inhibitor Sales by Country
  2. 10.1.1 South America VEGFR-2 Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America VEGFR-2 Inhibitor Sales by Country (2021-2026)
  4. 10.1.3 South America VEGFR-2 Inhibitor Sales Forecast by Country (2027-2032)
  5. 10.2 South America VEGFR-2 Inhibitor Market Size by Country
  6. 10.2.1 South America VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America VEGFR-2 Inhibitor Market Size by Country (2021-2026)
  8. 10.2.3 South America VEGFR-2 Inhibitor Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa VEGFR-2 Inhibitor Sales by Country
  2. 11.1.1 Middle East and Africa VEGFR-2 Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa VEGFR-2 Inhibitor Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa VEGFR-2 Inhibitor Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa VEGFR-2 Inhibitor Market Size by Country
  6. 11.2.1 Middle East and Africa VEGFR-2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa VEGFR-2 Inhibitor Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa VEGFR-2 Inhibitor Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 VEGFR-2 Inhibitor Value Chain Analysis
  2. 12.1.1 VEGFR-2 Inhibitor Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 VEGFR-2 Inhibitor Production Mode & Process
  7. 12.2 VEGFR-2 Inhibitor Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 VEGFR-2 Inhibitor Distributors
  10. 12.2.3 VEGFR-2 Inhibitor Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst